FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2015286376> ?p ?o ?g. }

• W2015286376 endingPage "57" @default.
• W2015286376 startingPage "55" @default.
• W2015286376 abstract "Despite their proven efficacy in stroke prevention, warfarin and antiplatelets remain underused. We determined the frequency of ischemic strokes attributable to underuse of warfarin and antiplatelets for stroke prevention in a Danish community. We included all patients with ischemic stroke in a Copenhagen community with 302,000 inhabitants admitted to the hospital between September 1999 and May 2000 (n = 426). Patients who did not receive warfarin or antiplatelet medication even though they were at known risk for cardiovascular disease before the incident stroke were identified; they had known atrial fibrillation, prior myocardial infarction, angina, or prior stroke transient ischemic attack (TIA). Sufficient information on cardiovascular risk factors before stroke was available in 404 patients. A total of 54 patients had atrial fibrillation known before the stroke. Of these, 16 had not received warfarin or antiplatelets on admission, 27 had not received warfarin but had received antiplatelets, and 11 had received warfarin. Assuming that warfarin and antiplatelets reduces the risk of stroke by 66% and 25%, respectively, it was calculated that between 6 and 12 of these strokes with atrial fibrillation could have been prevented if warfarin or antiplatelets had been given before stroke. A total of 147 patients had known stroke/TIA and/or myocardial infarction/angina before stroke (41 patients had not received antiplatelets on admission). If antiplatelet therapy had been given before stroke, 10 of these strokes could have been prevented. Our findings indicate that underuse of warfarin and antiplatelets is still of considerable magnitude and attributable to 4% to 5% (16 to 22 out of 404) of the ischemic strokes in a Danish urban community. Despite their proven efficacy in stroke prevention, warfarin and antiplatelets remain underused. We determined the frequency of ischemic strokes attributable to underuse of warfarin and antiplatelets for stroke prevention in a Danish community. We included all patients with ischemic stroke in a Copenhagen community with 302,000 inhabitants admitted to the hospital between September 1999 and May 2000 (n = 426). Patients who did not receive warfarin or antiplatelet medication even though they were at known risk for cardiovascular disease before the incident stroke were identified; they had known atrial fibrillation, prior myocardial infarction, angina, or prior stroke transient ischemic attack (TIA). Sufficient information on cardiovascular risk factors before stroke was available in 404 patients. A total of 54 patients had atrial fibrillation known before the stroke. Of these, 16 had not received warfarin or antiplatelets on admission, 27 had not received warfarin but had received antiplatelets, and 11 had received warfarin. Assuming that warfarin and antiplatelets reduces the risk of stroke by 66% and 25%, respectively, it was calculated that between 6 and 12 of these strokes with atrial fibrillation could have been prevented if warfarin or antiplatelets had been given before stroke. A total of 147 patients had known stroke/TIA and/or myocardial infarction/angina before stroke (41 patients had not received antiplatelets on admission). If antiplatelet therapy had been given before stroke, 10 of these strokes could have been prevented. Our findings indicate that underuse of warfarin and antiplatelets is still of considerable magnitude and attributable to 4% to 5% (16 to 22 out of 404) of the ischemic strokes in a Danish urban community." @default.
• W2015286376 created "2016-06-24" @default.
• W2015286376 creator A5006264676 @default.
• W2015286376 creator A5025060304 @default.
• W2015286376 creator A5042292099 @default.
• W2015286376 creator A5061586831 @default.
• W2015286376 date "2005-03-01" @default.
• W2015286376 modified "2023-09-27" @default.
• W2015286376 title "Strokes attributable to underuse of warfarin and antiplatelets" @default.
• W2015286376 cites W1969245357 @default.
• W2015286376 cites W1973441636 @default.
• W2015286376 cites W1986513552 @default.
• W2015286376 cites W2022095549 @default.
• W2015286376 cites W2030918284 @default.
• W2015286376 cites W2061365796 @default.
• W2015286376 cites W2071737611 @default.
• W2015286376 cites W2086228950 @default.
• W2015286376 cites W2086342651 @default.
• W2015286376 cites W2114428908 @default.
• W2015286376 cites W2127851526 @default.
• W2015286376 cites W2134968660 @default.
• W2015286376 cites W2151136808 @default.
• W2015286376 cites W2158454439 @default.
• W2015286376 cites W2166503147 @default.
• W2015286376 cites W2253894159 @default.
• W2015286376 cites W2407674438 @default.
• W2015286376 cites W2492141817 @default.
• W2015286376 cites W2529190803 @default.
• W2015286376 cites W311320695 @default.
• W2015286376 cites W3143864252 @default.
• W2015286376 cites W2030189178 @default.
• W2015286376 doi "https://doi.org/10.1016/j.jstrokecerebrovasdis.2004.11.003" @default.
• W2015286376 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17904001" @default.
• W2015286376 hasPublicationYear "2005" @default.
• W2015286376 type Work @default.
• W2015286376 sameAs 2015286376 @default.
• W2015286376 citedByCount "7" @default.
• W2015286376 countsByYear W20152863762015 @default.
• W2015286376 countsByYear W20152863762020 @default.
• W2015286376 crossrefType "journal-article" @default.
• W2015286376 hasAuthorship W2015286376A5006264676 @default.
• W2015286376 hasAuthorship W2015286376A5025060304 @default.
• W2015286376 hasAuthorship W2015286376A5042292099 @default.
• W2015286376 hasAuthorship W2015286376A5061586831 @default.
• W2015286376 hasConcept C126322002 @default.
• W2015286376 hasConcept C127413603 @default.
• W2015286376 hasConcept C164705383 @default.
• W2015286376 hasConcept C2776301958 @default.
• W2015286376 hasConcept C2777628954 @default.
• W2015286376 hasConcept C2778425758 @default.
• W2015286376 hasConcept C2779161974 @default.
• W2015286376 hasConcept C2780645631 @default.
• W2015286376 hasConcept C500558357 @default.
• W2015286376 hasConcept C71924100 @default.
• W2015286376 hasConcept C78519656 @default.
• W2015286376 hasConceptScore W2015286376C126322002 @default.
• W2015286376 hasConceptScore W2015286376C127413603 @default.
• W2015286376 hasConceptScore W2015286376C164705383 @default.
• W2015286376 hasConceptScore W2015286376C2776301958 @default.
• W2015286376 hasConceptScore W2015286376C2777628954 @default.
• W2015286376 hasConceptScore W2015286376C2778425758 @default.
• W2015286376 hasConceptScore W2015286376C2779161974 @default.
• W2015286376 hasConceptScore W2015286376C2780645631 @default.
• W2015286376 hasConceptScore W2015286376C500558357 @default.
• W2015286376 hasConceptScore W2015286376C71924100 @default.
• W2015286376 hasConceptScore W2015286376C78519656 @default.
• W2015286376 hasIssue "2" @default.
• W2015286376 hasLocation W20152863761 @default.
• W2015286376 hasLocation W20152863762 @default.
• W2015286376 hasOpenAccess W2015286376 @default.
• W2015286376 hasPrimaryLocation W20152863761 @default.
• W2015286376 hasRelatedWork W2014876946 @default.
• W2015286376 hasRelatedWork W2058741266 @default.
• W2015286376 hasRelatedWork W2064430680 @default.
• W2015286376 hasRelatedWork W2114223015 @default.
• W2015286376 hasRelatedWork W2140623030 @default.
• W2015286376 hasRelatedWork W2172069617 @default.
• W2015286376 hasRelatedWork W2241853559 @default.
• W2015286376 hasRelatedWork W2408189509 @default.
• W2015286376 hasRelatedWork W2415605004 @default.
• W2015286376 hasRelatedWork W1583736724 @default.
• W2015286376 hasVolume "14" @default.
• W2015286376 isParatext "false" @default.
• W2015286376 isRetracted "false" @default.
• W2015286376 magId "2015286376" @default.
• W2015286376 workType "article" @default.